Novartis Fights Bid To Invalidate Blood Transfusion Drug IP

Law360, London (April 19, 2021, 2:51 PM BST) -- Novartis AG has taken a stand against generic-drug maker Teva's claims that the pharmaceutical giant's intellectual property for a blood transfusion medicine should be revoked, denying that prior medical advances would have made its patented invention obvious.

In its defense filed with the High Court on Wednesday, Novartis denied that the two patents challenged by Teva Pharmaceutical Industries Limited are invalid.

The patented drug sold by Novartis under the brand name Exjade is called deferasirox. The drug is used to reduce chronic iron overload in patients who are receiving long-term blood transfusions for a disorder called beta thalassemia, as well as...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!